scispace - formally typeset
Search or ask a question
Topic

Artificial endocrine pancreas

About: Artificial endocrine pancreas is a research topic. Over the lifetime, 212 publications have been published within this topic receiving 21335 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter reduces morbidity and mortality among critically ill patients in the surgical intensive care unit.
Abstract: Background Hyperglycemia and insulin resistance are common in critically ill patients, even if they have not previously had diabetes. Whether the normalization of blood glucose levels with insulin therapy improves the prognosis for such patients is not known. Methods We performed a prospective, randomized, controlled study involving adults admitted to our surgical intensive care unit who were receiving mechanical ventilation. On admission, patients were randomly assigned to receive intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg per deciliter) or conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter and maintenance of glucose at a level between 180 and 200 mg per deciliter). Results At 12 months, with a total of 1548 patients enrolled, intensive insulin therapy reduced mortality during intensive care from 8.0 percent with conventional treatment to 4.6 percent (P<0.04, with adjustment for sequential analyses). The ...

8,748 citations

Journal ArticleDOI
TL;DR: In this large, international, randomized trial, it was found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg perDeciliter.
Abstract: Background: The optimal target range for blood glucose in critically ill patients remains unclear. Methods: Within 24 hours after admission to an intensive care unit (ICU), adults who were expected to require treatment in the ICU on 3 or more consecutive days were randomly assigned to undergo either intensive glucose control, with a target blood glucose range of 81 to 108 mg per deciliter (4.5 to 6.0 mmol per liter), or conventional glucose control, with a target of 180 mg or less per deciliter (10.0 mmol or less per liter). We defined the primary end point as death from any cause within 90 days after randomization. Results: Of the 6104 patients who underwent randomization, 3054 were assigned to undergo intensive control and 3050 to undergo conventional control; data with regard to the primary outcome at day 90 were available for 3010 and 3012 patients, respectively. The two groups had similar characteristics at baseline. A total of 829 patients (27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control group died (odds ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 1.28; P=0.02). The treatment effect did not differ significantly between operative (surgical) patients and nonoperative (medical) patients (odds ratio for death in the intensive-control group, 1.31 and 1.07, respectively; P=0.10). Severe hypoglycemia (blood glucose level, < or = 40 mg per deciliter [2.2 mmol per liter]) was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the conventional-control group (P<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU (P=0.84) or hospital (P=0.86) or the median number of days of mechanical ventilation (P=0.56) or renal-replacement therapy (P=0.39). Conclusions: In this large, international, randomized trial, we found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter. (ClinicalTrials.gov number, NCT00220987.)

4,241 citations

Journal ArticleDOI
TL;DR: Four aspects of encapsulated cells that are critical for the success of the technology, namely the capsule permeability, mechanical properties, immune protection and biocompatibility, have been singled out and methods to evaluate these properties were summarized.

762 citations

Journal ArticleDOI
TL;DR: The wearable artificial endocrine pancreas, incorporating the needle-type glucose sensor, a computer calculating infusion rates of insulin, glucagon, or both, and infusion pumps, was tested in pancreatectomised dogs and produced perfect control of blood glucose for up to 7 days.

578 citations

Journal ArticleDOI
TL;DR: A needle-type glucose sensor has been developed using a platinum electrode covered with immobilized glucose oxidase using a microcomputer system and a pump driving mechanism that could maintain the daily glucose variations in diabetic dogs within the range 5–9.5 mmol/l for 7 days.
Abstract: A needle-type glucose sensor has been developed using a platinum electrode covered with immobilized glucose oxidase. Experiments with albumin-saline solution in vitro showed that at 5.5 mmol/l glucose concentration the output current generated was 1.2±0.4 nA (mean ± SD). The current increased as a linear function of glucose concentration over the range (0–27.7 mmol/l). The response time to reach 90% of the final plateau value was 16.2±6.2 s. The signal-to-noise ratio of the sensor was 15.8±2.6 decibels. The temperature coefficient in output was 2.3±1.0%/°C. The current output was not affected significantly by changes in oxygen tension of the solution in the range 25–150 mmHg.

405 citations

Network Information
Related Topics (5)
Insulin
124.2K papers, 5.1M citations
79% related
Type 2 diabetes
69.6K papers, 3M citations
75% related
Insulin resistance
82.4K papers, 3.8M citations
74% related
Diabetes mellitus
169.2K papers, 6M citations
74% related
Leptin
22.7K papers, 1.1M citations
68% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20212
20201
20194
20181
20171
20152